Oubari Pharma
Oubari Pharma is a family-owned Syrian pharmaceutical manufacturer founded in 1989 in Aleppo, producing 350+ generic and licensed drugs across 15 delivery systems for domestic healthcare providers and distributors in 8+ Middle Eastern and African countries.
- Company typePrivate
- Founded1989
- HeadquartersAleppo
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Oubari Pharma does
Oubari Pharma (أوبري للصناعات الدوائية) is a private, family-owned Syrian pharmaceutical manufacturer founded in 1989 in Aleppo and headquartered at Al-Shahba, with a 50,000 m² production facility on 120,000 m² of land in the environmentally clean Al-Zerbeh area 20 km outside the city. It was the first private pharmaceutical company in Syria to manufacture injectable medicines in sterilized areas, and today produces more than 350 generic and licensed pharmaceutical products across 15 delivery systems (tablets, capsules, syrups, ampoules, suppositories, eye drops, vials, creams, ointments, sterile IV bottles, soft gelatin capsules, effervescent tablets) spanning therapeutic categories including analgesics, anti-infectives, cardiovascular, respiratory, neurological, NSAIDs, ophthalmics, and nutritional supplements. The company holds GMP, ISO 9001, ISO 14001, and OHSAS 18001 certifications, operates an in-house R&D department established in 2000, and sources raw materials and machinery from global suppliers including BASF, Merck, Pfizer, DSM, Sanofi Aventis, AMCOR, Schott, Bausch + Stroebel, Glatt, and Romaco.
The firm operates 500+ personnel under multi-generational family management founded by Mohammed Oubari, Mustafa Oubari, Ibrahim Radwan, and George Marash. Its revenue model combines direct pharmaceutical product sales, contract manufacturing services for international clients (20+ years of experience), and licensed production under agreements with European pharmaceutical companies (Rhone Poulenc, Roussel Uclaf, Dr. Mann, Lisa Pharma). Distribution runs through a dual-channel approach: a national network of agents covering all major Syrian cities, and an international export channel reaching Iraq, Yemen, Sudan, Algeria, Libya, Mauritania, Azerbaijan, and Jordan since 1994, with stated intent to expand further.
Oubari Pharma firmographics
Firmographics- Name
- Oubari Pharma
- Legal name
- Oubari for Pharmaceutical Industries
- Website
- https://oubari.com
- Company type
- Private
- Founded year
- 1989
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Oubari Pharma is a family-owned Syrian pharmaceutical manufacturer founded in 1989 in Aleppo, producing 350+ generic and licensed drugs across 15 delivery systems for domestic healthcare providers and distributors in 8+ Middle Eastern and African countries.
- Ownership category
- akta.pro rank
Oubari Pharma industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
- akta.pro secondary industry
- Oral Solid Dose (OSD) Generics (HLAIABAD)
Keywords
Where Oubari Pharma is headquartered
LocationHeadquarters
- HQ city
- Aleppo
Offices3 records
Markets served
Oubari Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Manufacture and sale of generic and licensed pharmaceutical products including injectables, oral dosage forms, tablets, capsules, syrups, suppositories, and other pharmaceutical preparations
- Contract Manufacturing: Offers contract manufacturing services to international clients with over 20 years of experience in manufacturing over 350 products spread across 15 different delivery systems
- Licensed Product Manufacturing: Production of pharmaceutical products under license from international pharmaceutical companies
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
Oubari Pharma product offering
Product offeringCore offering
Oubari Pharma manufactures generic pharmaceutical products across more than 15 delivery systems, including sterile injectables, oral dosage forms (tablets, capsules, syrups, and suspensions), topical preparations, and nutritional supplements. The company operates GMP-certified manufacturing facilities in Aleppo, Syria, producing over 350 SKUs and exporting to 8+ countries across the Middle East and Africa. Oubari also offers contract manufacturing services for international pharmaceutical firms, leveraging its quality certifications (GMP, ISO 9001, ISO 14001, OHSAS 18001) and large-scale 50,000 m² production footprint.
Product overview
Oubari Pharma is a Syrian pharmaceutical company established in 1989, operating as a generic drug manufacturer with over 350 products across 15 different delivery systems. The company produces a wide range of generic and licensed drugs organized into therapeutic categories including Analgesics & Antipyretics, Anti-Infectives, Cardiovascular Drugs, Respiratory System Drugs, Neurological Drugs, NSAIDs, Nutritional Supplements, and Ophthalmics. Product formulations include Tablets, Capsules, Syrups, Ampoules, Suppositories, Eye Drops, Vials, Creams, Ointments, and other dosage forms. The company emphasizes quality manufacturing with GMP compliance and ISO certifications.
Differentiator
Problem solved
Functional benefit
Products and services
- Sterile Injectables Injectable pharmaceutical products manufactured under sterile conditions at Oubari's Aleppo GMP facility.
- Oral Tablets and Capsules
Quantifiable outcome
- 350+ pharmaceutical products manufactured across 15 delivery systems
- +2 more outcomes
Companies that use Oubari Pharma
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Oubari Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Oubari Pharma partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core.
- Rhone PoulenccoreLicensing partnership for production of pharmaceutical products under license from this renowned European manufacturer
- Roussel UclafcoreLicensing partnership for production of pharmaceutical products under license from this renowned European manufacturer
- Dr. ManncoreLicensing partnership for production of pharmaceutical products under license from this German manufacturer
- Lisa PharmacoreLicensing partnership for production of pharmaceutical products under license
- International Raw Material Suppliers (BASF, Merck, Pfizer, DSM, Sanofi Aventis, Sandoz)coreGlobal leaders in raw materials supply including BASF, Merck, Pfizer Centersource, DSM, Farchemia, FMC, Gattefosse, Shin Etsu, and others ensuring high-quality input materials
- International Packaging Suppliers (AMCOR, Schott, SGD, Helvoet)corePremium packaging material suppliers including AMCOR, Helvoet, Klockner, Rexam Pharma, Sarong, Scandolara, Schott, and SGD ensuring product integrity
- International Machinery Suppliers (Bausch + Stroebel, Glatt, Fette, Romaco)coreState-of-the-art pharmaceutical machinery from Bausch + Stroebel, Brevetti, De Lama, Fette, Glatt, Manesty, Mediseal, MG2, Munters, Romaco, and Stilmas
Scale indicators8 records
Recent moves9 records
Expansion highlights5 records
Oubari Pharma competitors and assessment
Company assessmentDirect peers
- Hikma Pharmaceuticals: Jordan-headquartered generic and specialty pharmaceutical manufacturer with a multi-dosage form portfolio and strong MENA distribution presence; directly comparable to Oubari in target customers, generics focus, and regional channel reach.
- Julphar (Gulf Pharmaceutical Industries): UAE-based generic pharmaceutical manufacturer with one of the largest MENA production footprints and broad dosage form coverage; comparable on scale, regional export orientation, and generic product mix.
- Pharco Pharmaceuticals: Largest Egyptian generic pharmaceutical group with broad dosage form portfolio and MENA/Africa distribution; comparable on generic focus, multi-format manufacturing, and export-oriented regional strategy.
- EIPICO (Egyptian International Pharmaceutical Industries): Major Egyptian generic pharmaceutical manufacturer producing tablets, capsules, injectables, syrups, and sterile products for local and MENA/Africa export markets; directly comparable on dosage form breadth and regional channels.
- Dar Al Dawa: Jordanian generic pharmaceutical manufacturer producing across multiple dosage forms for MENA and export markets; directly comparable on generics positioning and regional go-to-market.
- SPIMACO: Saudi Pharmaceutical Industries & Medical Appliances Corporation, a leading Saudi generic and branded drug manufacturer serving MENA; comparable on portfolio breadth, regional export footprint, and GMP-driven manufacturing.
Broad incumbents
- Cipla: India-based global generic pharmaceutical leader with extensive sterile injectable, respiratory, and multi-dosage form portfolio including MENA/Africa distribution; relevant incumbent comparable on generics breadth and emerging-markets channel strategy.
- Aurobindo Pharma: Large Indian generic manufacturer with broad sterile injectable and oral dosage capability, exporting globally including MENA/Africa; incumbent comparison on portfolio depth and cost-competitive generics.
- Sanofi: Global diversified pharmaceutical company with a substantial generics and specialty care footprint across MENA/Africa; relevant broad incumbent given Oubari's historical licensing relationship and ongoing presence in branded-and-generic licensing arrangements.
Regional players
- Atabay: Turkey-headquartered generic pharmaceutical manufacturer with GMP-certified facilities producing tablets, sterile injectables, and other dosage forms; comparable in generics and injectable capability, though primarily serving Turkey and select export markets.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Oubari Pharma social profiles
Digital presenceOubari Pharma compliance and trust
Trust signalCompliance7 records
Oubari Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oubari Pharma leadership team
Management profileNumber of profiles
Profiles4 records
Oubari Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oubari Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oubari Pharma
What does Oubari Pharma do?
Oubari Pharma manufactures generic pharmaceutical products across more than 15 delivery systems, including sterile injectables, oral dosage forms (tablets, capsules, syrups, and suspensions), topical preparations, and nutritional supplements. The company operates GMP-certified manufacturing facilities in Aleppo, Syria, producing over 350 SKUs and exporting to 8+ countries across the Middle East and Africa. Oubari also offers contract manufacturing services for international pharmaceutical firms, leveraging its quality certifications (GMP, ISO 9001, ISO 14001, OHSAS 18001) and large-scale 50,000 m² production footprint.
Is Oubari Pharma a public or private company?
Oubari Pharma is a private company. It is classified as family owned and is currently operating.
When was Oubari Pharma founded?
Oubari Pharma was founded in 1989. It employs 501 to 1,000 people.
Where is Oubari Pharma based?
Oubari Pharma is headquartered in Aleppo.
How does Oubari Pharma make money?
Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are contract Manufacturing and licensed Product Manufacturing.
Who are Oubari Pharma's main competitors?
Direct peers on record are Hikma Pharmaceuticals, Julphar (Gulf Pharmaceutical Industries), Pharco Pharmaceuticals, EIPICO (Egyptian International Pharmaceutical Industries), Dar Al Dawa and SPIMACO. Broad incumbents are Cipla, Aurobindo Pharma and Sanofi. Atabay is listed as a regional player.
Does Oubari Pharma have an API?
No public API is recorded for Oubari Pharma.
What industry is Oubari Pharma in?
Oubari Pharma's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIABAD, Oral Solid Dose (OSD) Generics. Its NAICS code is 325412 and its SIC code is 2834.